Visit https://www.peervoice.com/VGT860 to view the entire programme with slides. After completing “Breaking the Cycle of Severe Hypoglycemia in Diabetes: Educating Clinicians and Patients Alike”, participants will be able to: Identify patients at risk of severe hypoglycemia; Evaluate the benefits and limitations of current pharmacologic strategies for the management of severe hypoglycemia; and Formulate approaches for educating patients and their caregivers about severe hypoglycemia and early and appropriate treatment.

Visit https://www.peervoice.com/TWQ860 to view the entire programme with slides. After completing “Transforming Management of Early-Stage EGFR-Mutant NSCLC: Insights From the Latest Data”, participants will be able to: Explain the rationale for targeted therapy in early-stage EGFR-mutant NSCLC; Assess recent clinical data for EGFR tyrosine kinase inhibitors (TKIs) as adjuvant therapy for patients with early-stage EGFR-mutant NSCLC; and Describe how EGFR TKIs may impact the treatment paradigm for early-stage EGFR-mutant NSCLC.

Visit https://www.peervoice.com/PEB860 to view the entire programme with slides. After completing “Practical Approaches to Optimise Management of Advanced Renal Cell Carcinoma”, participants will be able to: Outline an approach to maximise efficacy while managing toxicity associated with tyrosine kinase inhibitors (TKI) in patients with advanced renal cell carcinoma (RCC); Describe best practices for implementing this approach in clinical practice; and Identify areas to optimise management of patients on TKIs.

Visit https://www.peervoice.com/CPA860 to view the entire programme with slides. After completing “Extending Overall Survival in Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC) While Maintaining Quality of Life: Can We Have it All?”, participants will be able to: Evaluate recent survival data associated with androgen receptor (AR)-targeted therapies in patients with nmCRPC; Discuss why quality of life (QoL) should be prioritised when managing patients with nmCRPC; and Propose treatment plans for patients with nmCRPC that optimally balance efficacy with QoL, with a focus on adverse events.

Visit https://www.peervoice.com/XEF860 to view the entire programme with slides. After completing “Defining Control in Moderate-to-Severe Asthma: Where Are We Now and What Can We Do?”, participants will be able to: Recognise limitations regarding current concepts of asthma control; Understand the role of biomarkers in the treatment of moderate-to-severe asthma; and Develop targeted strategies for assessing and managing moderate-to-severe asthma.

Visit https://www.peervoice.com/AJN860 to view the entire programme with slides. After completing “Unmet Needs in Familial Mediterranean Fever (FMF): Real-Life Data, the Patient Perspective, and the Role of Anti–IL-1 Therapy”, participants will be able to: Characterise the incidence and impact of colchicine resistance among patients with FMF; Understand disease burden from the perspective of the patient; and Analyse the long-term clinical and quality-of-life (QoL) data for anti–IL-1 therapy in colchicine-resistant FMF.

Visit https://www.peervoice.com/ATJ860 to view the entire programme with slides. After completing “Best Practices for MET Mutation Testing in NSCLC: The Role of the Oncologist and the Pathologist”, participants will be able to: Discuss the rationale for MET biomarker testing in patients with non–small-cell lung cancer (NSCLC); Describe current testing modalities for patients with NSCLC and recent advances in identifying novel mutations; and Apply MET biomarker testing as standard of care for patients with NSCLC.

Visit https://www.peervoice.com/VYU860 to view the entire programme with slides. After completing “Novel Therapies for Patients With DLBCL: What Does the Future Hold?”, participants will be able to: Explain the rationale for novel therapeutic options for patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL); Evaluate the risk-benefit profiles of current and emerging therapies for the management of R/R DLBCL; and Incorporate available data on the use of novel anti-CD19 antibody strategies to treat R/R DLBCL into clinical practice.

Visit https://www.peervoice.com/QTK860 to view the entire programme with slides. After completing “New Targets in Heart Failure: Congress Updates on SGLT2 Inhibitors”, participants will be able to: Explain the rationale for SGLT2 inhibition in patients with heart failure (HF); Analyse clinical evidence for safety and efficacy of medical therapy such as SGLT2 inhibitors in patients with HF; and Describe the potential clinical implications of novel strategies on outcomes in HF.

Visit https://www.peervoice.com/QSX860 to view the entire programme with slides. After completing “Evaluating the Evidence for SGLT2 Inhibition in CKD”, participants will be able to: Explain the rationale for SGLT2 inhibition in patients with chronic kidney disease (CKD), based on mechanisms of action; Analyse clinical evidence for safety and efficacy of oral therapy such as SGLT2 inhibitors in patients with CKD; and Describe the potential clinical implications of novel strategies on outcomes in CKD.